Cited by 200Phytochemicals and Antioxidant ActivitiesPhytoestrogen effects and researchNutritional Studies and Diet

Chronic Ingestion of Flavan-3-ols and Isoflavones Improves Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in Medicated Postmenopausal Women With Type 2 Diabetes

Open access
Curtis, Peter J., Sampson, Mike, Potter, John, Dhatariya, Ketan, Kroon, Paul A., Cassidy, Aedín·2012·Diabetes Care

Abstract

OBJECTIVE: To assess the effect of dietary flavonoids on cardiovascular disease (CVD) risk in postmenopausal women with type 2 diabetes on established statin and hypoglycemic therapy. RESEARCH DESIGN AND METHODS: Despite being medicated, patients with type 2 diabetes have elevated CVD risk, particularly postmenopausal women. Although dietary flavonoids have been shown to reduce CVD risk factors in healthy participants, no long-term trials have examined the additional benefits of flavonoids to CVD risk in medicated postmenopausal women with type 2 diabetes. We conducted a parallel-design, placebo-controlled trial with type 2 diabetic patients randomized to consume 27 g/day (split dose) flavonoid-enriched chocolate (containing 850 mg flavan-3-ols [90 mg epicatechin] and 100 mg isoflavones [aglycone equivalents)]/day) or matched placebo for 1 year. RESULTS: Ninety-three patients completed the trial, and adherence was high (flavonoid 91.3%; placebo 91.6%). Compared with the placebo group, the combined flavonoid intervention resulted in a significant reduction in estimated peripheral insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR] −0.3 ± 0.2; P = 0.004) and improvement in insulin sensitivity (quantitative insulin sensitivity index [QUICKI] 0.003 ± 0.00; P = 0.04) as a result of a significant decrease in insulin levels (−0.8 ± 0.5 mU/L; P = 0.02). Significant reductions in total cholesterol:HDL-cholesterol (HDL-C) ratio (−0.2 ± 0.1; P = 0.01) and LDL-cholesterol (LDL-C) (−0.1 ± 0.1 mmol/L; P = 0.04) were also observed. Estimated 10-year total coronary heart disease risk (derived from UK Prospective Diabetes Study algorithm) was attenuated after flavonoid intervention (flavonoid +0.1 ± 0.3 vs. placebo 1.1 ± 0.3; P = 0.02). No effect on blood pressure, HbA1c, or glucose was observed. CONCLUSIONS: One-year intervention with flavan-3-ols and isoflavones improved biomarkers of CVD risk, highlighting the additional benefit of flavonoids to standard drug therapy in managing CVD risk in postmenopausal type 2 diabetic patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1443

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [1]International Diabetes Federation. IDF Diabetes Atlas, Fourth Edition Brussels, Belgium, International Diabetes Federation, 2009

Cited by

Sorted by citations

Authors
Curtis, P. J., Sampson, M., Potter, J., Dhatariya, K., Kroon, P. A., & Cassidy, A.
Affiliations
  • University of East Anglia (GB)
  • Norfolk and Norwich University Hospital (GB)
  • Quadram Institute (GB)
Corresponding author
Cassidy, Aedín
Venue
Diabetes Care
Published
2012-01-16
Volume
35
Issue
2
Pages
226-232
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2100144002
Cited by
200
References
39
Citations by year
2026: 4 · 2025: 10 · 2024: 10 · 2023: 14 · 2022: 19 · 2021: 11 · 2020: 15 · 2019: 12 · 2018: 21 · 2017: 15 · 2016: 21 · 2015: 17 · 2014: 9 · 2013: 14 · 2012: 8
FWCI
10.64
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion)
  • UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders
  • Diabetes UK (06/0003397)
  • Biotechnology and Biological Sciences Research Council (BBS/E/F/00043039, BBS/E/F/00044434)
Topics
  • Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Phytoestrogen effects and research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
flavan-3-ols, isoflavones, dietary flavonoids, type 2 diabetes, postmenopausal women, insulin sensitivity, insulin resistance, lipoprotein profile, cardiovascular risk, epicatechin, statin therapy, hypoglycemic therapy, coronary heart disease risk, HOMA-IR, QUICKI
MeSH terms
Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Female, Flavonoids, Humans, Insulin Resistance, Isoflavones, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Middle Aged, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review